Bionano (BNGO) Principal Accounting Officer Mark Adamchak Receives Award

What Happened
Mark Adamchak, Principal Accounting Officer of Bionano Genomics (BNGO), was granted a derivative award covering 5,000 shares on August 3, 2026. The reported acquisition price is $0.00 (i.e., an award/option grant rather than a cash purchase). This is an award (A) — not a sale — and does not reflect an immediate cash transaction.

Key Details

• Transaction date: 2026-08-03; Form filed: 2026-08-05 (this Form 4 replaces an earlier, erroneous Form 3 filed Aug 5, 2026).
• Transaction type: Award/Grant of a derivative instrument (option) for 5,000 shares at $0.00.
• Vesting: 50% of the options vest on each of the first and second anniversaries of the vesting commencement date, subject to continuous service (see footnote).
• Shares owned after transaction: Not specified in this filing.
• Timeliness: Filing date Aug 5, 2026; the report replaces an erroneous Form 3 — no late-filing flag noted in the document.

Context
This was a grant of a derivative award (an option) rather than an open-market buy or a sale. The award vests over two years (per footnote), so the economic benefit is tied to continued service and possible future share price performance; there is no immediate sale or cashless exercise reported. As always, grants indicate company compensation decisions and are not, by themselves, a clear buy/sell signal.